Actively Recruiting
Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
Led by Ospedale Policlinico San Martino · Updated on 2025-11-25
1200
Participants Needed
1
Research Sites
759 weeks
Total Duration
On this page
Sponsors
O
Ospedale Policlinico San Martino
Lead Sponsor
I
Istituto Italiano di Tecnologia
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and to obtain a new and more complete characterisation of subjects affected by the neurodegenerative diseases under study. Thanks to the integration of genomic, gene expression (transcriptomic and epigenomic), protein and metabolic data and clinical data, the study also aims to identify new markers for the diagnosis, prognosis, also in terms of response to therapy, and monitoring of neurodegenerative diseases. The study involves the enrolment of at least 1.200 individuals with neurodegenerative disease.
CONDITIONS
Official Title
Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients suffering from neurodegenerative diseases
You will not qualify if you...
- Patients not suffering from neurodegenerative diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ospedale Policlinico San Martino
Genoa, Genoa, Italy, 16132
Actively Recruiting
Research Team
P
Paola Mandich, MD, PhD
CONTACT
V
Vittorio Bocchini, Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here